PepGen Inc. (PEPG) shareholders
PEPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.36−0.68 (-13.49%)
Close on Nov 13, 2026Market cap $301.97MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.2%
52M of 69M shares
Institutional holders
72
7 new, 27 sold out
Net institutional buying
-5M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $59.31K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (29.20%), Rajeev Shah (29.20%) and 1 more | 20,099,753 | 29.20% | 13D (active) amendment | Sep 26, 2025 |
| Oxford Science Enterprises plc | 4,955,388 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Michael Kramarz Joint filing with Commodore Capital LP (6.50%), Commodore Capital Master LP (6.50%) and 1 more | 4,475,000 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital Master LP Joint filing with Commodore Capital LP (5.10%), Robert Egen Atkinson (5.10%) and 1 more | 3,544,101 | 5.10% | 13G (passive) | Mar 4, 2026 |
| Halvorsen Ole Andreas Joint filing with Viking Global Investors LP (5.10%), Viking Global Opportunities Parent GP LLC (5.10%) and 5 more | 3,482,434 | 5.10% | 13G (passive) | Sep 26, 2025 |
| Viking Global Opportunities GP LLC Joint filing with Viking Global Investors LP (5.03%), Viking Global Opportunities Parent GP LLC (5.03%) and 4 more | 3,482,434 | 5.03% | 13G (passive) amendment | Mar 31, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (9.80%) | 3,193,097 | 9.80% | 13G (passive) | Dec 31, 2024 |
| Suvretta Capital Management, LLC Joint filing with Averill Master Fund, LTD. (5.10%), Aaron Cowen (5.10%) | 1,660,932 | 5.10% | 13G (passive) | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PEPG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 20,064,545 | 28.97% | $36.12M | – | 0.31% |
| Commodore Capital LP | 4,475,000 | 6.46% | $8.06M | – | 0.48% |
| Viking Global Investors LP | 3,482,434 | 5.03% | $6.27M | – | 0.02% |
| Laurion Capital Management LP | 2,750,855 | 3.97% | $4.95M | – | 0.13% |
| ADAR1 Capital Management, LLC | 2,591,085 | 3.74% | $4.66M | +983,447 | 0.21% |
| Vivo Capital, LLC | 2,325,000 | 3.36% | $4.19M | – | 0.38% |
| Vanguard Capital Management LLC | 1,935,920 | 2.80% | $3.48M | −1,779 | 0.00% |
| Millennium Management LLC | 1,786,765 | 2.58% | $3.22M | −292,378 | 0.00% |
| Renaissance Technologies LLC | 1,520,246 | 2.19% | $2.74M | +1,463,446 | 0.00% |
| BlackRock, Inc. | 1,304,262 | 1.88% | $2.35M | +26,478 | 0.00% |
| Marshall Wace, Llp | 866,992 | 1.25% | $1.56M | +568,424 | 0.00% |
| Gsa Capital Partners Llp | 852,852 | 1.23% | $1.54M | +814,566 | 0.10% |
| Citadel Advisors LLC | 658,381 | 0.95% | $1.19M | +450,459 | 0.00% |
| AWM Investment Company, Inc. | 600,000 | 0.87% | $1.08M | −1,230,925 | 0.09% |
| Monimus Capital Management, LP | 587,688 | 0.85% | $1.06M | −10,975 | 0.24% |
| Squarepoint Ops LLC | 529,083 | 0.76% | $952.35K | +382,487 | 0.00% |
| Geode Capital Management, LLC | 523,473 | 0.76% | $942.81K | −12,526 | 0.00% |
| Creek Drive Management Group LLC | 450,000 | 0.65% | $810.00K | – | 0.39% |
| Ikarian Capital, LLC | 447,165 | 0.65% | $804.90K | – | 0.09% |
| Diadema Partners LP | 373,284 | 0.54% | $671.91K | +222,359 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 52M | 75.2% | 7 / 21 | 26 / 27 | 6M | 10M |
| Q1 2026 | 93 | 57M | 81.7% | 27 / 27 | 27 / 20 | 13M | 12M |
| Q4 2025 | 87 | 57M | 83.0% | 29 / 29 | 16 / 12 | 10M | 9M |
| Q3 2025 | 72 | 57M | 82.0% | 32 / 19 | 19 / 12 | 37M | 3M |
| Q2 2025 | 52 | 23M | 33.5% | 5 / 17 | 20 / 25 | 1M | 3M |
| Q1 2025 | 72 | 25M | 36.6% | 23 / 17 | 18 / 11 | 6M | 6M |
| Q4 2024 | 61 | 25M | 36.1% | 12 / 19 | 14 / 13 | 4M | 5M |
| Q3 2024 | 62 | 25M | 36.6% | 14 / 19 | 14 / 12 | 4M | 3M |
| Q2 2024 | 61 | 25M | 36.3% | 13 / 24 | 14 / 8 | 2M | 1M |
| Q1 2024 | 56 | 25M | 35.7% | 17 / 20 | 12 / 3 | 9M | 1M |
| Q4 2023 | 42 | 16M | 23.5% | 4 / 14 | 14 / 5 | 2M | 2M |
| Q3 2023 | 43 | 17M | 24.0% | 5 / 10 | 14 / 6 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
25 funds held PEPG in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PEPG | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,408,449 | 2.03% | $2.54M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 480,909 | 0.69% | $865.64K | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 448,519 | 0.65% | $807.33K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 230,248 | 0.33% | $345.37K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 140,776 | 0.20% | $253.40K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 86,249 | 0.12% | $129.37K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 86,000 | 0.12% | $154.80K | 0.10% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 69,170 | 0.10% | $103.76K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 42,675 | 0.06% | $64.01K | 0.00% | May 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 42,601 | 0.06% | $63.90K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,673 | 0.04% | $48.01K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 19,889 | 0.03% | $35.80K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 9,517 | 0.01% | $17.13K | 0.01% | Jun 30, 2026 |
| JNL/DFA U.S. Small Cap Fund | 5,789 | 0.01% | $10.42K | 0.00% | Jun 30, 2026 |
| Invesco Nasdaq Biotechnology ETF | 3,627 | 0.01% | $5.44K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| James G. McArthur | President and CEO, Director | 296,457 | 0.43% | Mar 6, 2026 |
| Kasra Kasraian | Chief Technical Officer | 50,074 | 0.07% | May 26, 2026 |
| Noel Donnelly | Chief Financial Officer | 111,603 | 0.16% | Mar 6, 2026 |
| Paul Streck | EVP, Head of R&D | 76,226 | 0.11% | Mar 6, 2026 |
| Joseph Vittiglio | Chief Business & Legal Officer | 65,717 | 0.09% | Mar 2, 2026 |
| Mary Beth DeLena | General Counsel | 14,968 | 0.02% | Mar 5, 2025 |
| Laurie Keating | Director | 4,166 | 0.01% | Jun 22, 2026 |
| Joshua Resnick | Director | – | – | Jun 22, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 18,554,273 | 26.79% | Jun 22, 2026 |
| Howard Mayer | Director | – | – | Jun 22, 2026 |
| Lisa Wyman | Director | – | – | Jun 22, 2026 |
| Mitchell H. Finer | Director | – | – | Jun 22, 2026 |
| Habib J. Dable | Director | – | – | Jun 22, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 22, 2026 |
| Peter Kolchinsky | Director, 10% owner | 9,179,273 | 13.25% | Jun 22, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Jun 22, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | – | – | Jun 22, 2026 |
| Heidi Henson | Director | – | – | Jun 22, 2026 |
| Science Enterprises plc Oxford | – | 4,955,388 | 7.15% | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kasra Kasraian Chief Technical Officer | May 21, 2026 | Sale(10b5-1 plan) | −1,233 | $1.41 | $1.74K | 50,074 |
| Noel Donnelly Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −52 | $6.33 | $329 | 111,603 |
| Noel Donnelly Chief Financial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,032 | $6.23 | $12.66K | 111,655 |
| James G. McArthur President and CEO, Director | Mar 4, 2026 | Sale(10b5-1 plan) | −5,144 | $6.23 | $32.05K | 296,457 |
| James G. McArthur President and CEO, Director | Mar 4, 2026 | Sale(10b5-1 plan) | −131 | $6.33 | $829 | 296,326 |
| Paul Streck EVP, Head of R&D | Mar 4, 2026 | Sale(10b5-1 plan) | −47 | $6.29 | $296 | 76,226 |
| Paul Streck EVP, Head of R&D | Mar 4, 2026 | Sale(10b5-1 plan) | −1,832 | $6.23 | $11.41K | 76,273 |
| Noel Donnelly Chief Financial Officer | Mar 1, 2026 | Award | +76,793 | – | – | 113,687 |
| James G. McArthur President and CEO, Director | Mar 1, 2026 | Award | +187,688 | – | – | 301,601 |
| Paul Streck EVP, Head of R&D | Mar 1, 2026 | Award | +50,300 | – | – | 78,105 |
| Joseph Vittiglio Chief Business & Legal Officer | Mar 1, 2026 | Award | +30,717 | – | – | 65,717 |
| Kasra Kasraian Chief Technical Officer | Mar 1, 2026 | Award | +34,557 | – | – | 51,307 |
| Joseph Vittiglio Chief Business & Legal Officer | Dec 8, 2025 | Award | +35,000 | – | – | 35,000 |
| Science Enterprises plc Oxford – | Sep 30, 2025 | Buy | +200,000 | $3.20 | $640.00K | 4,955,388 |
| Capital Healthcare Fund LP RA Director, 10% owner | Sep 26, 2025 | Buy | +9,375,000 | $3.20 | $30.00M | 18,554,273 |
| Paul Streck EVP, Head of R&D | May 30, 2025 | Buy | +8,375 | $1.24 | $10.39K | 27,805 |
| Kasra Kasraian Chief Technical Officer | May 20, 2025 | Award | +16,750 | – | – | 16,750 |
| James G. McArthur President and CEO, Director | Apr 17, 2025 | Buy | +10,000 | $1.36 | $13.60K | 113,913 |
| James G. McArthur President and CEO, Director | Apr 8, 2025 | Buy | +41,500 | $1.15 | $47.72K | 103,913 |
| Noel Donnelly Chief Financial Officer | Mar 3, 2025 | Award | +23,283 | – | – | 24,956 |
| Mary Beth DeLena General Counsel | Mar 3, 2025 | Award | +13,400 | – | – | 14,968 |
| Paul Streck EVP, Head of R&D | Mar 3, 2025 | Award | +19,430 | – | – | 19,430 |
| James G. McArthur President and CEO, Director | Mar 3, 2025 | Award | +60,719 | – | – | 62,413 |
| Noel Donnelly Chief Financial Officer | Feb 26, 2025 | Sale(10b5-1 plan) | −1,527 | $1.68 | $2.57K | 1,673 |
| Mary Beth DeLena General Counsel | Feb 26, 2025 | Sale(10b5-1 plan) | −1,432 | $1.68 | $2.41K | 1,568 |
| Noel Donnelly Chief Financial Officer | Feb 24, 2025 | Award | +3,200 | – | – | 3,200 |
| Mary Beth DeLena General Counsel | Feb 24, 2025 | Award | +3,000 | – | – | 3,000 |
| Michelle L. Mellion Chief Medical Officer | Jul 25, 2024 | Sale(10b5-1 plan) | −7,571 | $18.06 | $136.73K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 25, 2024 | Option exercise | +7,571 | $10.21 | $77.30K | 7,571 |
| Michelle L. Mellion Chief Medical Officer | Jul 24, 2024 | Sale(10b5-1 plan) | −201 | $18.01 | $3.62K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 24, 2024 | Option exercise | +201 | $10.21 | $2.05K | 201 |
| Michelle L. Mellion Chief Medical Officer | Jul 18, 2024 | Option exercise | +12,625 | $10.21 | $128.90K | 12,625 |
| Michelle L. Mellion Chief Medical Officer | Jul 18, 2024 | Sale(10b5-1 plan) | −12,625 | $18.20 | $229.78K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 16, 2024 | Sale(10b5-1 plan) | −5,901 | $18.00 | $106.22K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 16, 2024 | Option exercise | +5,901 | $10.21 | $60.25K | 5,901 |
| Michelle L. Mellion Chief Medical Officer | Jul 12, 2024 | Sale(10b5-1 plan) | −3,288 | $18.04 | $59.32K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 12, 2024 | Option exercise | +3,288 | $10.21 | $33.57K | 3,288 |
| Michelle L. Mellion Chief Medical Officer | Jul 2, 2024 | Option exercise | +37 | $10.21 | $378 | 37 |
| Michelle L. Mellion Chief Medical Officer | Jul 2, 2024 | Sale(10b5-1 plan) | −37 | $18.07 | $669 | 0 |
| Michelle L. Mellion Chief Medical Officer | Jul 1, 2024 | Option exercise | +875 | $10.21 | $8.93K | 875 |
| Michelle L. Mellion Chief Medical Officer | Jul 1, 2024 | Sale(10b5-1 plan) | −875 | $18.01 | $15.76K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 24, 2024 | Option exercise | +9,260 | $10.21 | $94.54K | 9,260 |
| Michelle L. Mellion Chief Medical Officer | Jun 24, 2024 | Sale(10b5-1 plan) | −9,260 | $18.19 | $168.44K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 12, 2024 | Option exercise | +1,086 | $10.21 | $11.09K | 1,086 |
| Michelle L. Mellion Chief Medical Officer | Jun 12, 2024 | Sale(10b5-1 plan) | −1,086 | $18.06 | $19.61K | 0 |
| Michelle L. Mellion Chief Medical Officer | Jun 11, 2024 | Option exercise | +500 | $10.21 | $5.11K | 500 |
| Michelle L. Mellion Chief Medical Officer | Jun 11, 2024 | Sale(10b5-1 plan) | −500 | $18.04 | $9.02K | 0 |
| Michelle L. Mellion SVP, Clinical Development | Jun 6, 2024 | Sale(10b5-1 plan) | −1,411 | $18.00 | $25.40K | 0 |
| Michelle L. Mellion SVP, Clinical Development | Jun 6, 2024 | Option exercise | +1,411 | $10.21 | $14.41K | 1,411 |
| Michelle L. Mellion SVP, Clinical Development | Jun 5, 2024 | Option exercise | +7,245 | $10.21 | $73.97K | 7,245 |
| Michelle L. Mellion SVP, Clinical Development | Jun 5, 2024 | Sale(10b5-1 plan) | −7,245 | $18.09 | $131.06K | 0 |
| Niels Svenstrup SVP, Chem. Mfg & Controls | May 17, 2024 | Sale(10b5-1 plan) | −10,000 | $13.41 | $134.10K | 0 |
| Peter Kolchinsky Director, 10% owner | Feb 9, 2024 | Buy | +2,557,593 | $10.64 | $27.21M | 9,179,273 |
| James G. McArthur President and CEO, Director | Nov 30, 2023 | Buy | +1,694 | $4.17 | $7.06K | 1,694 |
| James G. McArthur President and CEO, Director | Jun 8, 2023 | Sale(10b5-1 plan) | −2,381 | $16.04 | $38.19K | 0 |
| James G. McArthur President and CEO, Director | Jun 8, 2023 | Option exercise | +2,381 | $2.71 | $6.45K | 2,381 |
| James G. McArthur President and CEO, Director | Jun 7, 2023 | Sale(10b5-1 plan) | −8,419 | $16.23 | $136.64K | 0 |
| James G. McArthur President and CEO, Director | Jun 7, 2023 | Option exercise | +8,419 | $2.71 | $22.82K | 8,419 |
| James G. McArthur President and CEO, Director | Jun 6, 2023 | Sale(10b5-1 plan) | −18,150 | $16.18 | $293.67K | 0 |
| James G. McArthur President and CEO, Director | Jun 6, 2023 | Option exercise | +18,150 | $2.71 | $49.19K | 18,150 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
8.55%
3M shares short
Days to cover
2.8
At 1M shares a day
Change since last report
-11.5%
From 4M shares
Short volume, 20 days
48.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of PepGen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 56,548 shares on Oct 6, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michelle L. Mellion Officer | Jun 5, 2024 | 50,000 | $788.00K | Jun 5, 2024 | Exercise of Stock Options |
| Niels Svenstrup Officer | May 17, 2024 | 10,000 | $136.50K | May 17, 2024 | Previously Exercised Stock Options |
| Goyal Jaya Officer | Mar 12, 2024 | 116,187 | $2.06M | Mar 12, 2024 | STOCK OPTION EXERCISE |
| James G. McArthur Officer | Jun 2, 2023 | 31,250 | $460.94K | Jun 2, 2023 | Exercise of Stock Options |
See a number that looks wrong?